There are 25 papers on oropharyngeal cancer in aging research: 1 trial and 15 observational studies in people, 7 reviews.
25 papers study it14 more mention it8 findings
2 new papers in 30 daysSee all 39 papers on oropharyngeal cancer
“Taking more than 1 multivitamin daily was also strongly positively associated with the risk of oropharyngeal cancer in women (HR, 1.53, 95% CI: 1.04-2.24; P-trend < 0.0001).”
- Human trial1
- Humans15
- In silico2
Upstream
1Telomere length
no changein silico1OR 0.999
1 study
Telomere length
no changein silico1OR 0.999
Telomere length showed no clear effect on oropharyngeal cancer in silico (OR = 0.999, 95% CI 0.998-1.001, P = .650).
In silico
Associations
7Wildfire-specific particulate matter 2.5
upin humans1
1 study
Wildfire-specific particulate matter 2.5
upin humans1
Wildfire-specific particulate matter 2.5 is associated with oropharyngeal cancer in humans (cRR 1.09 (95% CI 1.06–1.13)).
Humansoropharynx
OPC risk prediction models
upin silico1
1 study
OPC risk prediction models
upin silico1
OPC risk prediction models predict oropharyngeal cancer in internal validation.
In silicoin internal validation
Human papillomavirus infection
upin humans1
1 study
Human papillomavirus infection
upin humans1
Human papillomavirus infection is linked with a higher risk of oropharyngeal cancer in humans (AAPC 9.65% (95% CI: 5.81-13.62)).
Humansmales
HPV16-E6 antibodies
upin humans1
1 study
HPV16-E6 antibodies
upin humans1
HPV16-E6 antibodies predict oropharyngeal cancer in humans (meta-analysis of HPV-OPC detection) (sensitivity 83.1%, specificity 94.6%).
Reviewmeta-analysis of HPV-OPC detection
Inflammatory tongue condition
upin humans1OR 1.3
1 study
Inflammatory tongue condition
upin humans1OR 1.3
Inflammatory tongue condition is linked with a higher risk of oropharyngeal cancer in humans (preceding cancer/control selection by >12 months) (OR 1.3, 95% CI 1.0-1.6).
Humanspreceding cancer/control selection by >12 months
Multivitamin
upin humans1HR 1.53
1 study
Multivitamin
upin humans1HR 1.53
Multivitamin is linked with a higher risk of oropharyngeal cancer in humans (HR 1.53, 95% CI: 1.04-2.24).
Humans>1 dailyfemalesn = 489,640
Human papillomavirus vaccine
downin silico1
1 study
Human papillomavirus vaccine
downin silico1
Human papillomavirus vaccine lowers the risk of oropharyngeal cancer in silico (by 2045) (48.1% men, 42.5% women (36-45); 9.0% men, 22.6% women (46-55)).
In silicoby 2045
Trial sponsors
Company1 trialPhase 127 people
Company1 trialPhase 117 people
Universitaetsklinikum Hamburg-Eppendorf
1 trialPhase 4280 people
2 trialsPhase 3538 people
2 trialsPhase 3253 people
1 trialPhase 3785 people
Johannes Gutenberg University Mainz
1 trialPhase 3209 people
1 trialPhase 3110 people
Funding
10 grants since 2017National Institute of Dental and Craniofacial Research$9.6MNational Cancer Institute$431KBaylor College of Medicine$177K
Screening for HPV-related oropharyngeal cancer
National Institute of Dental and Craniofacial ResearchJohns Hopkins University$980K2026–2028
National Institute of Dental and Craniofacial ResearchUniversity of Maryland Baltimore$562K2024–2029
HPV-related Oropharyngeal Cancer Screening and Monitoring through Remote Self-Sampling
National Institute of Dental and Craniofacial ResearchBaylor College of Medicine$677K2024–2029
HPV16 E6 Antibody Detection as an Early Marker for Oropharyngeal Cancer Among Men Living with HIV
National Institute of Dental and Craniofacial ResearchUniversity of Kentucky$219K2021–2026
Baylor College of MedicineThe University of Texas MD Anderson Cancer Center$50.8K2025
HPV16 E6 Seropositivity and ctHPVDNA for Early Detection of Oropharyngeal Cancer
American Cancer Society2024–2028
Circulating HPV DNA as a Prediagnostic Marker of Oropharyngeal Cancer
National Cancer InstituteUniversity of Kentucky$147K2022–2025
AI-Driven Large-scale Screening for Oral and Oropharyngeal Cancer
VINNOVAUppsala UniversitySEK 2.5M2021–2023
The role of germline and somatic DNA mutations in oral and oropharyngeal cancers
National Institute of Dental and Craniofacial ResearchInternational Agency for Res on Cancer$706K2017–2022